ORCID as entered in ROS

Select Publications
2023, 'PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 84 - 84
,2017, 'The plasma lipidome in castration-resistant prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.5055
,2013, 'The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419605294&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, 'Overcoming Docetaxel Resistance in Prostate Cancer by Targeting FAK Phosphorylation, and Its Mode of Action', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, IRELAND, European Org Res & Treatment Canc (EORTC), Dublin, pp. 48 - 49, presented at 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, IRELAND, European Org Res & Treatment Canc (EORTC), Dublin, 06 November 2012 - 09 November 2012, http://dx.doi.org/10.1016/S0959-8049(12)71956-1
,2024, 'Abstract 5480: Single cell and spatial transcriptomic profile of appendiceal tumour peritoneal disease', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. 5480 - 5480, http://dx.doi.org/10.1158/1538-7445.am2024-5480
,2024, '1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)', in Annals of Oncology, Elsevier BV, Vol. 35, pp. S969 - S970, http://dx.doi.org/10.1016/j.annonc.2024.08.1688
,2022, 'Single-cell transcriptomic analysis of appendiceal cancer peritoneal disease', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S1322 - S1322, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.1791
,2022, 'Patient-derived explant model of appendiceal cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022
,2022, 'Patient-derived explant model of appendiceal cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 4160 - 4160, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.4160
,2022, 'Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.154
,2021, 'Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S666 - S667, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1148
,2021, 'Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S642 - S643, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1109
,2020, 'Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 80, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-4761
,2019, 'Company Profiles', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 15, pp. 33 - 33, http://dx.doi.org/10.1111/ajco.13198
,2019, 'Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.230
,2023, Data from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer, http://dx.doi.org/10.1158/1541-7786.c.6540204.v1
,2023, Data from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer, http://dx.doi.org/10.1158/1541-7786.c.6540204
,2023, Supplementary Figures 1-3 from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer, http://dx.doi.org/10.1158/1541-7786.22512309.v1
,2023, Supplementary Figures 1-3 from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer, http://dx.doi.org/10.1158/1541-7786.22512309
,